Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience

Assaf Moore, Yael Bar, Corinne Maurice-Dror, Inbar Finkel, Hadar Goldvaser, Elizabeth Dudnik, Daniel A. Goldstein, Noa Gordon, Salem Billan, Orit Gutfeld, Ido Wolf, Aron Popovtzer

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

ABSTRACT: Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers.Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8-66.6] and2 months (CI95% 0.2-16.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7-111.4 months) and was 77.8 months (CI95% 52.5-114.6) for patients treated conventionally (P = .3).NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.

Original languageEnglish
Pages (from-to)e26388
JournalMedicine (United States)
Volume100
Issue number25
DOIs
StatePublished - 25 Jun 2021
Externally publishedYes

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience'. Together they form a unique fingerprint.

Cite this